A catalytic dependent role for DNMT3B in tumor suppression

doi:10.1016/j.ebiom.2021.103237

Comment

. 2021 Mar:65:103237.

doi: 10.1016/j.ebiom.2021.103237. Epub 2021 Mar 11.

A catalytic dependent role for DNMT3B in tumor suppression

Haitao Li¹, Mario Andrés Blanco²

Affiliations

¹ Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
² Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA. Electronic address: ablanco@vet.upenn.edu.

PMID: 33714886
PMCID: PMC7966975
DOI: 10.1016/j.ebiom.2021.103237

Comment

A catalytic dependent role for DNMT3B in tumor suppression

Haitao Li et al. EBioMedicine. 2021 Mar.

. 2021 Mar:65:103237.

doi: 10.1016/j.ebiom.2021.103237. Epub 2021 Mar 11.

Authors

Haitao Li¹, Mario Andrés Blanco²

Affiliations

¹ Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA.
² Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA. Electronic address: ablanco@vet.upenn.edu.

PMID: 33714886
PMCID: PMC7966975
DOI: 10.1016/j.ebiom.2021.103237

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have nothing to declare.

Comment on

Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription.
Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Fuks F, et al. EMBO J. 2001 May 15;20(10):2536-44. doi: 10.1093/emboj/20.10.2536. EMBO J. 2001. PMID: 11350943 Free PMC article.

Cited by

Association study of ESR1 rs9340799, rs2234693, and MMP2 rs243865 variants in Iranian women with premature ovarian insufficiency: A case-control study.
Sadat Eshaghi F, Dehghan Tezerjani M, Ghasemi N, Dehghani M. Sadat Eshaghi F, et al. Int J Reprod Biomed. 2022 Nov 2;20(10):841-850. doi: 10.18502/ijrm.v20i10.12268. eCollection 2022 Oct. Int J Reprod Biomed. 2022. PMID: 36381354 Free PMC article.

References

1. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400–5413. - PubMed
1. Kiel M.J. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nat Commun. 2015;6 - PMC - PubMed
1. Campbell R.M., Tummino P.J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Investig. 2014;124:64–69. - PMC - PubMed
1. Fuks F., Burgers W.A., Godin N., Kasai M., Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001;20:2536–2544. - PMC - PubMed
1. Zheng Y. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia. 2016;30:2373–2384. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

Grants and funding

K22 CA214849/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400–5413. - PubMed

[2] Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400–5413. - PubMed

[3] Kiel M.J. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nat Commun. 2015;6 - PMC - PubMed

[4] Kiel M.J. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome. Nat Commun. 2015;6 - PMC - PubMed

[5] Campbell R.M., Tummino P.J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Investig. 2014;124:64–69. - PMC - PubMed

[6] Campbell R.M., Tummino P.J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Investig. 2014;124:64–69. - PMC - PubMed

[7] Fuks F., Burgers W.A., Godin N., Kasai M., Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001;20:2536–2544. - PMC - PubMed

[8] Fuks F., Burgers W.A., Godin N., Kasai M., Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 2001;20:2536–2544. - PMC - PubMed

[9] Zheng Y. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia. 2016;30:2373–2384. - PubMed

[10] Zheng Y. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia. 2016;30:2373–2384. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A catalytic dependent role for DNMT3B in tumor suppression

Affiliations

A catalytic dependent role for DNMT3B in tumor suppression

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources